Elanco Q2 2026 earnings: Innovation demand lifts revenue and margins

Elanco Animal Health (NYSE: ELAN) reported Q2 2026 revenue of $1.368 billion, up 10% from $1.241 billion a year earlier, while diluted GAAP EPS rose to $0.11 from $0.02. Organic constant-currency growth was 8%, and adjusted EBITDA increased 21% to $288 million as innovation products strengthened U.S. Pet Health mix; operating cash flow also rose to $277 million.

Core earnings data

Revenue benefited from both volume and pricing, led by demand for Zenrelia and Credelio Quattro in Pet Health and growth across the global ruminant portfolio. Organic constant-currency growth excludes foreign exchange effects, revenue from AHV International following its April 30 acquisition, and royalty revenue sold to a third party.

Profit increased faster than revenue. Favorable U.S. Pet Health mix and pricing lifted gross margin, while GAAP net income also benefited from a substantially lower effective tax rate.

Dollar figures are in millions except per-share data.

Adjusted net income, adjusted EPS, and adjusted EBITDA are non-GAAP measures and should be considered alongside the reported results.

Business and segment performance

Pet Health remained the primary growth driver, while Farm Animal growth was concentrated in cattle and other ruminant products. Swine was the only disclosed species category with declining revenue.

Pet Health volume increased 9%, primarily because of demand for Zenrelia and Credelio Quattro, while pricing contributed another 2%. The established Advantage product family generated $154 million of revenue, and Seresto contributed $117 million.

Farm Animal volume rose 3% and pricing added 2%. Global ruminants was Elanco’s fastest-growing species group, increasing 12% organically at constant currency and 17% when including AHV International and foreign exchange effects.

Innovation-led mix outweighed launch and inflation costs

The quarter’s central operating theme was the relationship between innovation-driven mix and higher commercial spending. Reported and adjusted gross margins each improved by 80 basis points, primarily because stronger U.S. Pet Health performance and pricing more than offset higher inventory costs caused by inflation.

At the same time, marketing, selling, and administrative expenses increased 12% to $449 million because of global product-launch investments and higher compensation. R&D remained unchanged at $92 million. Gross profit rose by approximately $85 million, compared with an approximately $49 million increase in combined R&D and marketing, selling, and administrative expenses, allowing adjusted EBITDA to grow faster than revenue.

Profitability, cash flow, and the balance sheet

The increase in GAAP net income was not entirely operational. Elanco’s reported effective tax rate fell to 3.3% from 55.4%, reflecting a more favorable geographic mix of earnings and the absence of prior-year discrete tax changes. The adjusted tax rate declined to 17.8% from 21.7%.

Reported net interest expense increased by $11 million to $59 million. The main factors were $15 million of imputed interest related to the sale of future revenue and interest associated with the corporate headquarters finance lease, partially offset by lower average debt balances. Adjusted net interest expense, which excludes the imputed interest, was $44 million.

Operating cash flow increased to $277 million. Elanco ended the quarter with company-defined net debt of $3.159 billion and a net leverage ratio of 3.1 times trailing adjusted EBITDA, down 0.5 times from December 31, 2025. Cash and cash equivalents totaled $530 million.

Earnings guidance

Elanco raised its full-year revenue, adjusted EBITDA, and adjusted EPS ranges. The company also narrowed the organic growth range upward and now expects faster gross-margin expansion than it projected in May.

At the midpoints, adjusted EBITDA guidance represents 13% year-over-year growth and adjusted EPS guidance represents 20% growth. Elanco also raised its innovation revenue target to $1.25 billion and improved its year-end net leverage target to approximately 3.0 times adjusted EBITDA.

Full-year reported revenue is expected to receive an approximately $60 million foreign-exchange benefit. Revenue guidance excludes royalty revenue sold to a third party, while organic growth also excludes foreign exchange and AHV International.

For Q3 2026, Elanco expects continued organic growth alongside additional spending to support innovation products.

The company expects foreign exchange to have a neutral year-over-year revenue effect in the third quarter.

Management perspective

CEO Jeff Simmons identified Zenrelia as the largest individual contributor to Elanco’s global growth, followed by Credelio Quattro. Management attributed U.S. Pet Health and U.S. Farm Animal organic constant-currency growth of 11% each to a combination of pricing, volume, innovation demand, and commercial execution.

CFO Bob VanHimbergen said early progress under the Elanco Ascend productivity program contributed to faster-than-planned margin expansion. The initiative remains targeted to generate $200 million to $250 million of net adjusted EBITDA savings by 2030, while the company continues investing in new-product launches and its R&D pipeline.

Recent insider transactions

Reported insider records list six purchases dated between December 11, 2025, and May 15, 2026, with a combined reported value of approximately $1.14 million. The transactions included both direct and indirect ownership.

The 10 latest entries in the supplied transaction record were direct, zero-price stock awards to directors on May 21, 2026. Those awards should not be treated as open-market purchases.

Risks investors need to watch

• Dependence on innovation products: Zenrelia and Credelio Quattro were the largest named growth drivers. Slower adoption or weaker market-share gains would affect Pet Health growth and the $1.25 billion innovation revenue target.
• Margin and spending execution: Inflation-related inventory costs partly offset Q2 gross-margin gains, while commercial and compensation expenses increased. Q3 operating expenses are expected to rise approximately 10% at constant currency.
• Leverage and interest costs: Net leverage improved to 3.1 times, but net debt remained $3.159 billion and reported quarterly interest expense increased to $59 million. Reaching the new leverage target depends on cash flow and EBITDA delivery.
• Foreign-exchange sensitivity: Full-year reported revenue guidance incorporates an approximately $60 million currency benefit, making reported growth sensitive to changes in exchange rates.
• Tax-related earnings volatility: The sharp increase in GAAP net income partly reflected the effective tax rate falling to 3.3%. Changes in geographic earnings mix or discrete tax items could affect future GAAP comparisons.

Summary

Elanco’s Q2 2026 results combined innovation-led volume growth, favorable Pet Health mix, wider margins, stronger operating cash flow, and lower leverage. Management responded by raising its full-year financial and innovation targets, but continued product-launch spending, inflation costs, interest expense, and execution against the deleveraging plan remain the main areas to monitor.

More questions

Why was adjusted EPS much higher than GAAP EPS?

Adjusted EPS of $0.34 excluded several items included in GAAP EPS of $0.11. The largest adjustment was $139 million of intangible-asset amortization, along with $9 million of restructuring and other special charges and $15 million of imputed interest expense; the reconciliation also included sold royalty revenue and related tax adjustments.

What does Elanco mean by organic constant-currency growth?

Elanco defines the measure as revenue growth excluding foreign-exchange effects, royalty revenue sold to a third party, and revenue from AHV International, which was acquired on April 30, 2026.